Stocks TelegraphStocks Telegraph
Stock Ideas

ABVC Financial Statements and Analysis

NASDAQ : ABVC

ABVC BioPharma

$1.10
0.03+2.80%
At Close 4:00 PM
63.71
BESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
revenue0795.95K00389.276K
cost of revenue0000296.00
gross profit0795.95K00388.98K
gross profit ratio01.00000.999
research and development expenses33.10K29.89K33.276K28.861K37.825K
general and administrative expenses002.262M664.144K0
selling and marketing expenses00000
selling general and administrative expenses751.998K1.934M2.262M664.144K301.208K
other expenses787.374K0000
operating expenses1.572M1.964M2.295M693.005K339.033K
cost and expenses01.964M2.295M693.005K339.329K
interest income3.765K16.327K19.139K19.071K44.261K
interest expense-49.377K0129.413K222.967K219.533K
depreciation and amortization05.821K80.832K113.948K7.014K
ebitda-1.572M-1.281M-2.099M-607.275K92.626K
ebitda ratio0-1.61000.238
operating income-1.572M-1.168M-2.295M-693.005K49.947K
operating income ratio0-1.468000.128
total other income expenses net-117.465K-118.586K-14.223K-251.185K-183.864K
income before tax-1.69M-1.287M-2.309M-944.19K-133.917K
income before tax ratio0-1.61700-0.344
income tax expense-1.56M527.0023.627K0355.00
net income-129.695K-1.247M-2.257M-842.075K-186.561K
net income ratio0-1.56600-0.479
eps-0.06-0.054-0.13-0.06-0.015
eps diluted-0.06-0.054-0.13-0.06-0.015
weighted average shs out25.449M23.257M17.387M14.968M12.405M
weighted average shs out dil25.449M23.257M17.387M14.968M12.405M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
cash and cash equivalents140.324K192.068K1.076M759.568K137.344K
short term investments62.185K65.175K65.211K65.052K70.809K
cash and short term investments202.509K257.243K1.142M824.62K208.153K
net receivables001.422M537.119K11.992K
inventory011.46K11.46K11.46K0
other current assets446.339K3.804M194.999K96.362K1.928M
total current assets648.848K4.073M2.77M1.47M2.148M
property plant equipment net14.65M12.425M8.675M8.702M8.439M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments1.846M2.745M2.838M2.76M2.334M
tax assets00000
other non current assets2.588M1.934M1.958M1.944M1.541M
total non current assets19.084M17.104M13.471M13.406M12.315M
other assets00000
total assets19.733M21.176M16.241M14.876M14.463M
account payables00000
short term debt1.22M1.227M2.137M2.823M2.184M
tax payables5.888K6.17K000
deferred revenue0081.115K81.115K79.50K
other current liabilities4.161M5.274M4.314M3.827M4.052M
total current liabilities5.393M6.508M6.533M6.731M6.316M
long term debt1.511M164.072K177.133K166.985K142.201K
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities012.00K41.679K21.68K25.68K
total non current liabilities1.511M176.072K218.812K188.665K167.881K
other liabilities00000
capital lease obligations1.843M363.407K00507.659K
total liabilities6.904M6.684M6.751M6.919M6.484M
preferred stock00000
common stock25.767K24.19K19.533K15.378K12.712K
retained earnings-78.419M-73.295M-72.049M-69.792M-70.552M
accumulated other comprehensive income loss499.65K487.048K1.574M475.212K461.282K
other total stockholders equity88.666M84.842M77.469M74.706M78.437M
total stockholders equity10.773M12.058M7.014M5.404M8.358M
total equity12.828M14.493M9.49M7.956M7.979M
total liabilities and stockholders equity19.733M21.176M16.241M14.876M14.463M
minority interest2.056M2.435M2.476M2.552M-379.144K
total investments1.908M2.81M2.903M2.825M2.405M
total debt2.731M1.391M2.314M2.99M2.326M
net debt2.591M1.199M1.238M2.23M2.189M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q2
deferred income tax00000
stock based compensation787.374K1.136M1.572M48.773K412.741K
change in working capital0-140.809K-389.463K-19.281K-514.367K
accounts receivables00054.113K-378.251K
inventory000-11.46K0
accounts payables00000
other working capital0-140.809K-389.463K-61.934K-23.17K
other non cash items-83.836K21.837K99.866K260.917K880.144K
net cash provided by operating activities-894.243K-133.257K-894.174K-539.833K-1.038M
investments in property plant and equipment00003.00
acquisitions net00000
purchases of investments00000
sales maturities of investments00000
other investing activites47.123K-1.273M-665.779K00
net cash used for investing activites47.123K-1.273M-665.779K00
debt repayment0150.00K0-29.25K-24.326K
common stock issued000411.667K737.50K
common stock repurchased00000
dividends paid00000
other financing activites-342.181K982.395K1.927M46.339K131.039K
net cash used provided by financing activities-342.181K1.132M1.927M428.756K892.866K
effect of forex changes on cash2.64K51.804K-50.616K6.83K229.324K
net change in cash-1.187M-222.415K316.758K-104.247K83.767K
cash at end of period0853.911K1.076M759.568K742.769K
cash at beginning of period01.076M759.568K863.815K659.002K
operating cashflow-894.243K-133.257K-894.174K-539.833K-1.038M
capital expenditure00003.00
free cash flow-894.243K-133.257K-894.174K-539.833K-1.038M
Graph

Frequently Asked Questions

How did ABVC BioPharma, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, ABVC generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did ABVC BioPharma, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. ABVC BioPharma, Inc. reported a $0.00 Gross Profit for the quarter ended Mar 31, 2026.
Have ABVC's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. ABVC incurred $1.57M worth of Operating Expenses, while it generated -$1.57M worth of Operating Income.
How much Net Income has ABVC posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from ABVC BioPharma, Inc., the company generated -$129.70K in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did ABVC BioPharma, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to ABVC BioPharma, Inc. as of the end of the last quarter was $140.32K.
What are ABVC's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, ABVC had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did ABVC BioPharma, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of ABVC were $648.85K, while the Total Assets stand at $19.73M.
As of the last quarter, how much Total Debt did ABVC BioPharma, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of ABVC's debt was $2.73M at the end of the last quarter.
What were ABVC's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, ABVC reported total liabilities of $6.90M.
How much did ABVC's Working Capital change over the last quarter?
Working Capital Change for ABVC was $0.00 over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
ABVC generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. ABVC generated -$894.24K of Cash from Operating Activities during its recently reported quarter.
What was ABVC's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. ABVC reported a -$1.19M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph